Grey Wolf reels in $49M to en­ter the clin­ic for new im­munother­a­py tar­get

When he finds the time to go fly fish­ing, Pe­ter Joyce says gray wulffs, or mayfly mim­ics, are his good luck charm — he al­ways catch­es a fish when he us­es them. Joyce has now brought in $49 mil­lion in a Se­ries B round for his biotech com­pa­ny Grey Wolf Ther­a­peu­tics.

The Ox­ford, UK can­cer biotech plans to use the funds to bring its first as­set in­to hu­man tri­als in the com­ing month or two, ac­cord­ing to Joyce. Pfiz­er Ven­tures and Early­bird Ven­ture Cap­i­tal co-led the round, which the start­up dis­closed Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER